Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postextrasystolic blood pressure potentiation predicts poor outcome of cardiac patients.
Sinnecker D, Dirschinger RJ, Barthel P, Müller A, Morley-Davies A, Hapfelmeier A, Dommasch M, Huster KM, Hasenfuss G, Laugwitz KL, Malik M, Schmidt G. Sinnecker D, et al. Among authors: laugwitz kl. J Am Heart Assoc. 2014 Jun 3;3(3):e000857. doi: 10.1161/JAHA.114.000857. J Am Heart Assoc. 2014. PMID: 24895163 Free PMC article. Clinical Trial.
Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Goedel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A, Laugwitz KL. Moretti A, et al. Among authors: laugwitz kl. N Engl J Med. 2010 Oct 7;363(15):1397-409. doi: 10.1056/NEJMoa0908679. Epub 2010 Jul 21. N Engl J Med. 2010. PMID: 20660394 Free article.
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, Seyfarth M, Pache J, Laugwitz KL, Büttner HJ, Ndrepepa G, Schömig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3A Trial Investigators. Schulz S, et al. Among authors: laugwitz kl. Eur Heart J. 2010 Oct;31(20):2482-91. doi: 10.1093/eurheartj/ehq330. Epub 2010 Aug 30. Eur Heart J. 2010. PMID: 20805113 Clinical Trial.
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Gudermann T, Lipp P, Laugwitz KL. Jung CB, et al. Among authors: laugwitz kl. EMBO Mol Med. 2012 Mar;4(3):180-91. doi: 10.1002/emmm.201100194. Epub 2012 Jan 25. EMBO Mol Med. 2012. PMID: 22174035 Free PMC article.
Induced pluripotent stem cells in cardiovascular research.
Sinnecker D, Dirschinger RJ, Goedel A, Moretti A, Lipp P, Laugwitz KL. Sinnecker D, et al. Among authors: laugwitz kl. Rev Physiol Biochem Pharmacol. 2012;163:1-26. doi: 10.1007/112_2012_6. Rev Physiol Biochem Pharmacol. 2012. PMID: 22447279 Review.
Modeling long-QT syndromes with iPS cells.
Sinnecker D, Goedel A, Dorn T, Dirschinger RJ, Moretti A, Laugwitz KL. Sinnecker D, et al. Among authors: laugwitz kl. J Cardiovasc Transl Res. 2013 Feb;6(1):31-6. doi: 10.1007/s12265-012-9416-1. Epub 2012 Oct 18. J Cardiovasc Transl Res. 2013. PMID: 23076501 Review.
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
Schulz S, Kastrati A, Ferenc M, Massberg S, Birkmeier KA, Laugwitz KL, Kufner S, Gick M, Dommasch M, Schühlen H, Schömig A, Berger PB, Mehilli J, Neumann FJ; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 4 Trial Investigators. Schulz S, et al. Among authors: laugwitz kl. EuroIntervention. 2013 Aug 22;9(4):430-6. doi: 10.4244/EIJV9I4A71. EuroIntervention. 2013. PMID: 23455033 Free article. Clinical Trial.
397 results